아다진 (ADAG) 주가

아다진(ADAG)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.31 (-1.78%), 시가총액 $0.23B, 52주 최저~최고 $1.41 ~ $4.61.

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and A

핵심 지표

• 현재가: $3.31 (-1.78%)
• 시가총액: $0.23B
• 52주 최저~최고: $1.41 ~ $4.61
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

아다진의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

아다진 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 3.3333

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 6.90
• 순이익률: -2.30%
• 영업이익률: -0.75%

자주 묻는 질문